Gilead Sciences

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Alkermes depression drug now looks promising, but will FDA bite?

Pharmalot By Ed Silverman

Gilead asks FDA to expand exclusivity for a key HIV drug

Pharmalot By Ed Silverman

Less than 1 percent of state prisoners with hepatitis C get treated due to drug costs

Pharmalot By Ed Silverman

European regulator amends some Gilead hep C patent claims

Pharmalot By Ed Silverman

Colorado is latest state to be sued for restricting access to hepatitis C drugs

In the Lab By Rebecca Robbins

The lab breakthrough that paved the way for today’s pricey hepatitis C cures

Pharmalot By Ed Silverman

Up and down the ladder: The latest comings and goings

Pharmalot By Ed Silverman

Doctors Without Borders urges Gilead to rethink its hepatitis C strategy in Ukraine

Pharmalot By Ed Silverman

University of Minnesota sues Gilead for infringing on hepatitis C patents

Pharmalot By Ed Silverman

ACLU threatens to sue Colorado over hepatitis C drug restrictions

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: North Korea’s Neo-Viagra has the same ingredient as the real thing

Pharmalot By Ed Silverman

IRS is urged to investigate Gilead for ‘dodging’ US taxes

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Valeant overhauls part of its management team

Pharmalot By Ed Silverman

Gilead fires back at medical journal report critical of its pricing

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Gilead’s preventive HIV pill must be covered in England

Pharmalot By Ed Silverman

Biotechs say that controversy over pricing is a bigger risk each year

Pharmalot By Ed Silverman

Gilead hep C drug prices blamed for England’s health service rationing treatment

Pharmalot By Ed Silverman

As hep C sales decline, Wall Street wonders what Gilead does for its next act

Pharmalot By Ed Silverman

Gilead avoided nearly $10 billion in taxes last year thanks to tax dodges

Pharmalot By Ed Silverman

Gilead defeats AIDS activists who claimed the company manipulated patents

Pharmalot By Ed Silverman

Gilead’s new price hikes on HIV drugs anger AIDS activists

Business By Rebecca Robbins

Gilead hikes price of HIV therapies, other drugs by up to 10 percent

Pharmalot By Ed Silverman

Gilead and Massachusetts agree to rebates for hep C drugs

Pharmalot By Ed Silverman

FDA approves a Gilead pill that is first to treat all forms of hepatitis C

Health By Associated Press

Most Read

Using force crossed my mind when examining a defiant young patient. A short story made me take a breath

The sale of Watson Health assets ends a dark chapter for IBM. For its buyer, the opportunity looks brighter

Up and down the ladder: The latest comings and goings

Once billed as a revolution in medicine, IBM’s Watson Health is sold off in parts

Pharmalittle: Alzheimer’s patient groups to protest Medicare plan for Biogen drug; cancer combo treatments are questioned

What genetic counselors can teach the CDC about communicating uncertainty

It’s staff, not stuff: Applying crisis standards of care to allocating health care workers

For doctors drowning in emails, one health system’s new strategy: pay for replies

All Coverage

Pharmalot, Pharmalittle: Alkermes depression drug now looks promising, but will FDA bite?

Gilead asks FDA to expand exclusivity for a key HIV drug

Less than 1 percent of state prisoners with hepatitis C get treated due to drug costs

European regulator amends some Gilead hep C patent claims

Colorado is latest state to be sued for restricting access to hepatitis C drugs

The lab breakthrough that paved the way for today’s pricey hepatitis C cures

Up and down the ladder: The latest comings and goings

Doctors Without Borders urges Gilead to rethink its hepatitis C strategy in Ukraine

University of Minnesota sues Gilead for infringing on hepatitis C patents

ACLU threatens to sue Colorado over hepatitis C drug restrictions

Pharmalot, Pharmalittle: North Korea’s Neo-Viagra has the same ingredient as the real thing

IRS is urged to investigate Gilead for ‘dodging’ US taxes

Pharmalot, Pharmalittle: Valeant overhauls part of its management team

Gilead fires back at medical journal report critical of its pricing

Pharmalot, Pharmalittle: Gilead’s preventive HIV pill must be covered in England

Biotechs say that controversy over pricing is a bigger risk each year

Gilead hep C drug prices blamed for England’s health service rationing treatment

As hep C sales decline, Wall Street wonders what Gilead does for its next act

Gilead avoided nearly $10 billion in taxes last year thanks to tax dodges

Gilead defeats AIDS activists who claimed the company manipulated patents

Gilead’s new price hikes on HIV drugs anger AIDS activists

Gilead hikes price of HIV therapies, other drugs by up to 10 percent

Gilead and Massachusetts agree to rebates for hep C drugs

FDA approves a Gilead pill that is first to treat all forms of hepatitis C

FDA approves first pill to treat all forms of hepatitis C